At the Perlmutter Cancer Center, The Thoracic Oncology Disease Management Group, through a collaborative approach, strive to provide state-of-the-art treatment for patients with all thoracic malignancies, and specifically lung cancer and mesothelioma.
This group includes leadership from:
- Nationally prominent thoracic surgical, medical, and radiation oncologists.
- Pulmonologists and Radiologists whose primary interest is thoracic malignancies
- Translational scientists focused on screening and early detection of malignancies as well as innovative therapies for the treatment of advanced stage disease.
Many patients with thoracic malignancies need treatment from different specialists. This group coordinates those specialists into a team approach centered on each patient.
Clinical research plays an essential role in the mission of the Thoracic Oncology DMG. Treatment trials at the Perlmutter Cancer Center are aimed at providing promising new therapies to patients. Many of our trials focus on targeted and immunotherapies. Research in the Thoracic Oncology DMG also focuses on screening and early detection of thoracic malignancies though the discovery and validation of novel biomarkers and innovative imaging techniques.
Our Thoracic Oncology Group Leaders have held top positions within the National Cancer Institute (NCI) and are recognized as pioneers in their respective fields.